Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.